Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 2, 2003, Pages 322-327

  Sironi, Luigi ^a   Cimino, Mauro ^b   Guerrini, Uliano ^a   Calvio, Anna Maria ^a   Lodetti, Barbara ^a   Asdente, Maria ^a   Balduini, Walter ^b   Paoletti, Rodolfo ^a   Tremoli, Elena ^a,c  

^a Dept of Pharmacological Sciences ^*  (Italy)

^b UNIVERSITY OF URBINO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Cerebral ischemia; Endothelial nitric oxide synthase; MRI; Rat; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE SYNTHASE; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DRUG EFFECT; ENDOTHELIUM CELL; IMMUNOREACTIVITY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN CHEMISTRY; BRAIN DAMAGE, CHRONIC; BRAIN INJURIES; BRAIN ISCHEMIA; BRAIN MAPPING; CEREBRAL ARTERIES; CEREBRAL CORTEX; CEREBRAL INFARCTION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MALE; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN; UP-REGULATION;

EID: 0037326964     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000044458.23905.3B     Document Type: Article

References (33)

1. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13.000 strokes in 450.000 people in 45 prospective cohorts. Lancet. 1995;346:1647-1653.
2. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ. Stroke. statins, and cholesterol: a meta-analysis of randomized, placebo-controlled. double-blind trials with HMG-CoA reductase inhibitors. Stroke. 1997;28: 946-950.
3. van Mil AHM, Westendorp RGJ, Bollen EL, Lagaay AM, Blauw GJ. HMG-CoA reductase inhibitors in the prevention of stroke. Drugs. 2000; 59:1-6.
4. Crouse JR, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis. 1998;140:193-194.
5. Faggiotto A, Paoletti R. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. Hypertension. 1999;34:987-996.
6. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke. 1999;30:1969-1973.
7. Hess DC, Demchuk AM, Brass LM, Yatsu FM. HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. Neurology. 2000;54:790-796.
8. Takemoto M. Liao JK. Pleiotropic effects of 3-hidroxy-3-methylglutaryl coenzyme A reductase inhibitors. Aterioscler Thromb Vasc Biol. 2001;21:1712-1719.
9. Delanty N, Vaughan CJ. Vascular effects of statins in stroke. Stroke. 1997;28:2315-2320.
10. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399-1402.
11. Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenyl-acetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest. 1997;100: 2671-2679.
12. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ. Sessa WC, Walsh K, The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
13. Aviram M, Rosenblat M, Biagaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Alherosclerosis. 1998;138:271-280.
14. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. Stroke protection by 3-hydroxy-3-mehylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1998;95:8880-8885.
15. Laufs U, Gertz K, Huang P, Nickening G, Bohm M. Dirnagl U, Endres M. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000;31:2437-2449.
16. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke. 2001;32:980-986.
17. Balduini W, De Angelis V, Mazzoni E, Cimino M. Simvastatin protects against long-lasting behavioural and morphological consequences of neonatal hypoxic/ischemic brain injury. Stroke. 2001;32:2181-2185.
18. Baird AE, Warach S. Magnetic resonance imaging of acute stroke. J Cereb Blood Flow Metab. 1998;18:583-609.
19. Hoen-Berlage M, Nicolay K, Franke C, van der Sprenkel JWB. Application of magnetic resonance to animal models of cerebral ischemia. J Magn Reson Imaging. 2001;14:491-509.
20. Gill R, Sibson NR, Maskell L, Carpenter TA, Hall LD, Pickard JD. The protective effect of MK-801 on infarct development over a period of 24h as assessed by diffusion-weighted magnetic resonance imaging. NMR Biomed. 1996;9:241-248.
21. Hoen-Berlage M. Diffusion-weighted NMR imaging: application to experimental focal cerebral ischemia. NMR Biomed. 1995;8:345-358.
22. Tamura A, Graham DI, McCullogh J, Teasdale MG. Focal cerebral ischemia in the rat, 1: description of technique and early neuropathological consequences following middle cerebral artery occlusion. J Cereb Blood Flow Metab. 1981;1:53-60.
23. Basser PJ. Inferring microstructural features and the physiological state of tissue from diffusion-weighted images. NMR Biomed. 1995;8:333-344.
24. Pierpaoli C, Jezzard P, Basser PJ, Barnett A, Di Chiro G. Diffusion tensor MR imaging of the human brain. Radiology. 1996;201:637-648.
25. Pierpaoli C, Righini A, Linfante I, Tao-Cheng JH, Alger JR, Di Chiro G. Histopathologic correlates of abnormal water diffusion in cerebral ischemia: diffusion-weighted MR Imaging and light and electron microscopic study. Radiology. 1993;189:439-448.
26. Marks MP, de Crespigny AJ, Lentz D, Enzmann DR, Albers GA, Moseley ME. Acute and chronic stroke: navigated spin-echo diffusion-weighted MR imaging. Radiology. 1996;199:403-408.
27. van Gelderen P, de Vleeschouwer HM, DesPres D, Pekar J, van Zijl PC, Moonen CT. Water diffusion and acute stroke. Magn Res Med. 1994;31: 154-163.
28. Knight RA, Ordidge RJ, Helpern JA, Chopp M. Temporal evolution and spatial distribution of the diffusion constant of water in rat brain after transient middle cerebral artery occlusion. Stroke. 1991;22:802-808.
29. Guerrini U, Sironi L, Tremoli E, Cimino M, Pollo B, Calvio AM, Paoletti R, Asdente M. New insights into brain damage in stroke-prone rats: a nuclear magnetic imaging study. Stroke. 2002;33:825-830.
30. Rudin M, Baumann B, Ekatodramis DSR, McAllister KH, Sauter A. MRI analysis of the changes in apparent water diffusion coefficient, T(2) relaxation time, and cerebral blood tlow and volume in the temporal evolution of cerebral infarction following permanent middle cerebral artery occlusion in rats. Exp Neurol. 2001;169:56-63.
31. Bucher HCGLE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1998;128:89-95.
32. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 6 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;2053:360:7-22.
33. Dalkara T, Morikawa E, Panahian N, Moskowitz MA. Blood flow-dependent functional recovery in a rat model of focal cerebral ischemia. Am J Physiol. 1994;267:H678-H683.